What is the Fischer Medical Ventures PE ratio today?
Fischer Medical Ventures' PE ratio is 105.9 at the 29 October 2026 close (₹25.93 a share): a market capitalisation of ₹1,697 crore divided by consolidated net profit of ₹16 crore over the last four quarters (Q2 FY26 to Q1 FY27). On FY26 net profit (₹31 crore) it is 54.7.
What is the Fischer Medical Ventures PB ratio (price to book value)?
Fischer Medical Ventures' price-to-book (PB) ratio is 4.42 at the 29 October 2026 close: a market capitalisation of ₹1,697 crore divided by shareholders' equity (book value) of ₹384 crore on 31 March 2026. That is a book value of ₹5.87 per share against a share price of ₹25.93.
What is the Fischer Medical Ventures net worth?
Fischer Medical Ventures' net worth — shareholders' equity in its consolidated balance sheet — was ₹384 crore on 31 March 2026. Its market value is a different figure: a market capitalisation of ₹1,697 crore at the 29 October 2026 close.
What is the Fischer Medical Ventures market cap?
Fischer Medical Ventures' market capitalisation was ₹1,697 crore at the 29 October 2026 close: 65.45 crore shares at ₹25.93 each.
Is Fischer Medical Ventures debt free?
No. Fischer Medical Ventures had borrowings of ₹72.4 crore on 31 March 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.19. Its cash and current investments were ₹25 crore, so its net debt was ₹47.3 crore.
What is the Fischer Medical Ventures debt to equity ratio?
Fischer Medical Ventures' debt-to-equity ratio was 0.19 on 31 March 2026: borrowings of ₹72.4 crore against total equity of ₹385 crore.
What is the Fischer Medical Ventures book value per share?
Fischer Medical Ventures' book value per share was ₹5.87 on 31 March 2026: shareholders' equity of ₹384 crore divided by the 65.45 crore shares in issue. The share price at the 29 October 2026 close was ₹25.93.
What is the Fischer Medical Ventures free cash flow?
In FY26, Fischer Medical Ventures generated ₹101 crore of cash from operations and spent ₹1.3 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of −₹103 crore.
When are the Fischer Medical Ventures next results?
Fischer Medical Ventures has not yet announced the date of its Q2 FY27 results (July–September 2026); under SEBI's listing rules (Regulation 33) they are due by 14 November 2026.
What is the Fischer Medical Ventures EPS?
Fischer Medical Ventures' basic earnings per share (EPS) were ₹0.48 in FY26.
What is the Fischer Medical Ventures dividend in 2026 and its record date?
In 2026, Fischer Medical Ventures has declared one dividend: ₹0.05 with record date 22 September 2026.
What is the Fischer Medical Ventures revenue and profit in FY26?
In FY26 (April 2025–March 2026), Fischer Medical Ventures' consolidated net profit was ₹31 crore, on revenue from operations of ₹309 crore.
What is the Fischer Medical Ventures promoter holding?
Promoters held 63.08% of Fischer Medical Ventures on 30 September 2026, up 0.93 percentage points from 62.15% the previous quarter and up 1.28 percentage points from 61.80% a year earlier, according to the shareholding pattern filed with NSE.
What are the Fischer Medical Ventures latest quarterly results?
Fischer Medical Ventures' latest results are for Q1 FY27 (April–June 2026), filed on 14 August 2026: consolidated net profit ₹3.8 crore, down 24.3% from ₹5 crore in Q1 FY26; revenue from operations ₹81.9 crore, up 249.4% year on year.
How does Fischer Medical Ventures compare with its peers?
On FY26 consolidated figures, against Tarsons Products, Laxmi Dental and Fabtech Technologies: Fischer Medical Ventures' operating margin of 13.0% is the highest of the four (Tarsons Products 5.1%, Laxmi Dental 9.9%, Fabtech Technologies 7.2%; peer average 7.4%).
What is the Fischer Medical Ventures shareholding pattern?
On 30 September 2026, Fischer Medical Ventures' shares were held by promoters 63.08%, foreign portfolio investors (FII/FPI) 6.71%, domestic institutions (DII) 1.26% (including mutual funds at 0.00%) and retail and other non-institutional investors 28.94%. Over the year, FII holding was up 1.14 percentage points from 5.57% and DII holding was down 0.16 percentage points from 1.42%.
How does the Fischer Medical Ventures PE ratio compare with its peers?
At the 29 October 2026 closing prices, on FY26 net profit, Fischer Medical Ventures' PE ratio is 54.7, the second highest of the four: Tarsons Products 112.9, Laxmi Dental 33.6 and Fabtech Technologies 14.2, a peer average of 53.6. Each is the company's market capitalisation at that price divided by its FY26 net profit.
Fischer Medical Ventures vs Tarsons Products: how do they compare?
In FY26, Fischer Medical Ventures earned net profit of ₹31 crore on revenue of ₹309 crore, against ₹14.3 crore on ₹423 crore for Tarsons Products. Fischer Medical Ventures' operating margin was 13.0% (Tarsons Products 5.1%). At the 29 October 2026 close, Fischer Medical Ventures' market capitalisation was ₹1,697 crore against ₹1,617 crore for Tarsons Products, and its PE ratio on FY26 profit 54.7 against 112.9.
Consolidated figures from the company's filings with NSE; prices are NSE closing prices.
